ResoTher Pharma wins prestigious Merck Advance Biotech Grant Award
ResoTher Pharma is extremely pleased to announce our nomination as winner of the European-wide 2019 Advance Biotech Awards, issued by German pharma conglomerate Merck AG. ResoTher Pharma was one of many European contestants for the prestigious award and was selected...
Joel Scherer, MD joins Scientific Advisory Board
ResoTher Pharma management is pleased to announce that Joel Scherer, MD has joined the company´s Scientific Advisory Board. Dr. Scherer brings considerable drug development and cardiology expertise from his former roles as Chief Medical Officer, Managing Director at...
Kirsten Drejer steps up as Chairwoman of ResoTher Pharma
Kirsten Drejer, PhD takes on the role as Chairwoman of the Board of ResoTher Pharma following a unanimous vote at the company´s general assembly. “We are extremely pleased with the collaboration with Kirsten, who has a wealth of experience to contribute to a company...
Thomas Engstrøm, MD joins Scientific Advisory Board
The management of ResoTher Pharma is pleased to announce that consulting cardiologist and Professor Thomas Engstrøm, MD joins the company´s scientific advisory board as an expert clinical advisor. Dr. Engstrøm is an expert in the diagnosis and treatment of Myocardial...
Kirsten Drejer joins Board of Directors
Jeppe Øvlesen, Chairman of ResoTher Pharma, is pleased to announce that biotech veteran Kirsten Drejer, PhD joins the Board of Directors effective immediately. Dr. Drejer brings with her significant leadership and company building experience from her many years as...
ResoTher Pharma closes seed round
ResoTher Pharma is pleased to announce the signing of its first round of investment, lead by CAPNOVA A/S and consisting of a handful of private DK and US-based investors. CEO Lone Veng, PhD will take leadership of the new entity, whose goal it is to clinically...
Relevant publications
- April 2017: Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide
- January 2017: Immune resolution mechanisms in inflammatory arthritis
- May 2013: Proresolving and Tissue-Protective Actions of Annexin A1−Based Cleavage-Resistant Peptides Are Mediated by Formyl Peptide Receptor 2/Lipoxin A4 Receptor
- January 2009: Annexin A1 and glucocorticoids as effectors of the resolution of inflammation
- June 2001: Involvement of the Receptor for Formylated Peptides in the in Vivo Anti-Migratory Actions of Annexin 1 and its Mimetics
- February 2001: Neutrophil Interaction with Inflamed Postcapillary Venule Endothelium Alters Annexin 1 Expression